FDA’s Nonclinical Testing Rule: What It Means for CROs Offering NAMs

By | Sep 28, 2026

US FDA's direct final rule rewrites drug and biologics regulations to cover in vitro, in silico, and organ-chip studies, giving NAM-ready CROs a clearer opening with sponsors